We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 1.28% | 7.91 | 7.88 | 7.95 | 8.00 | 7.89 | 7.92 | 1,433,488 | 21:31:23 |
By Colin Kellaher
Arvinas Inc. (ARVN) Tuesday said it will collaborate with Bayer AG (BAYN.XE) to develop new human therapeutics for patients with cardiovascular, oncological and gynecological diseases and will launch a joint venture with the German chemical-and-pharmaceutical company to develop targeted protein degraders for agricultural applications.
Arvinas, a New Haven, Conn., biopharmaceutical company, said the deal includes more than $110 million in upfront cash and committed funding for the collaboration, the venture and a direct equity investment by Bayer.
Trading in shares of Arvinas, which closed Monday at $20.05, was halted premarket Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 04, 2019 07:23 ET (11:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions